home | publications


1. The D’Amico Article Reviewed: The CPDR/CaPSURE Recurrence Equation.
Moul JW.
Oncology, 15:1060-1062, 2001.

2. Use of Serum Creatinine to Predict Pathologic Stage and Recurrence Among Radical Prostatectomy Patients.
Merseburger AS, Connelly RR, Sun L, Richter E, Moul JW:
Urology, 58:729-734, 2001.

3. The Development of Erectile Dysfunction in Men Treated for Prostate Cancer.
Siegel T, Moul JW, Spevak M, Alvord WG, and Costabile RA:
Journal of Urology, Vol. 165,430-435, 2001.

4. PSA Enhanced Testing and Risk Stratification for Chemoprevention Trials.
Moul JW:
Urology, 57 (Suppl 4A): 174-177, 2001.

5. A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group.
Lance RS, Freidrichs PA, Kane C, Powell CR, Pulos E, Moul JW, McLeod DG, Cornum RL, and Thrasher JB:
BJU International. Vol. 87:61-65, 2001.

6. Quantitative Expression Profile of Androgen-Regulated Genes in Prostate Cancer Cells and Identification of Prostate-Specific Genes.
Xu LL, Su YP, LaBiche R, Segawa T, Shanmugam N, McLeod, Moul JW and Srivastava S:
Int. J. Cancer, Vol. 92:322-328, 2001.

7. Clinical Staging of Prostate Cancer: Reproducibility and Clarification of Issues.
Campbell T, Blasko J, Crawford ED, Forman J, Hanks G, Kuban D, Montie J, Moul JW, Pollack A, Raghavan D, Ray P, Roach III M, Steinberg G, Stone N, Thompson I, Vogelzang N, and Vijayakumar S:
Int. J. Cancer. (Radiat. Oncol. Invest), 96:198-209, 2001.

8. Age-Specific Reference Ranges for Prostate Specific Antigen in Young Men: Retrospective Study from the National Defense University.
Hartzell JD, Kao TC, Holland JC, Holt SR, and Moul JW:
The Prostate Journal, 3:36-41, 2001.

9. The Effect of Ethnicity on Biochemical Disease-Free Outcome in Patients with Prostate Cancer Treated with Definitive Radiation Therapy in an Equal-Access Health Care System: A Radiation Oncology Report of the Department of Defense Center for Prostate Disease Research.
Johnstone P, Kane C, Sun L, Wu H, Moul JW, et al:
Radiology, 2001.

10. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.
Moul JW, Connelly RR, Lubeck DP, Bauer JJ, Sun L, Flanders SC, Grossfeld GD, Carroll PR:
J Urol, 166:1322-1327, 2001.

11. Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black men.
Bissonette EA, Fulmer BR, Petroni GR, Moul JW, Theodorescu D:
J Urol, 166:1328-31, 2001.

12. A novel human cancer culture model for the study of prostate cancer.
Yasunaga Y, Nakamura K, Ko D, Srivastava S, Moul JW, Sesterhenn IA, McLeod DG, Rhim J:
Oncogene, 20:8036-8041, 2001.

13. Changing face and different countenances of prostate cancer: Racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era.
Jani AB, Vaida F, Hanks, G, Asbell S, Sartor O, Moul JW, Raoch M 3rd, Brachman D, Kalokhe U, Muller-Runkel R, Ray P, Ignacio L, Awan A, Weichselbaum RR, and Vijayakumar S:
Int J Cancer, 96:363-371, 2001.

14. Improvements in Pathological Staging for African-American Men Undergoing Radical Retropubic Prostatectomy During the Prostate-Specific Antigen Era – Implications for Screening a High-Risk Group for Prostate Carcinoma.
Paquette EL, Connelly RR, Sesterhenn IA, Zhang W, Sun L, Paquette LR, Greenspan R, Mcleod DG, Moul, JW:
Cancer, 92:2673-2679, 2001.

15. Relationship Between Obesity and Race in Predicting Adverse Pathologic Variables in Patients Undergoing Radical Prostatectomy.
Amling CL, Kane CJ, Riffenburgh RH, Ward JF, Roberts JL, Lance RS, Freidrichs PA, Moul JW:
Urolog, 58:723-728,2001.

16. Managing advanced prostate cancer with Viadur (leuprolide acetate implant).
Moul JW, Civitelli K:
Urol Nurs, 21:385-8, 393-4; quiz 395-6, 2001.

17. Prostate biopsy protocols: 3D visualization-based evaluation and clinical correlation.
Zeng J, Bauer J, Zhang W, Sesterhenn I, Connelly R, Lynch J, Moul J, Mun SK:
Comput Aided Surg, 6:14-21, 2001.

18. The Role of Imaging Studies and Molecular Markers for Selecting Candidates for Radical Prostatectomy.
Moul JW, Kane CJ, and Malkowicz SB:
Urol Clinics of North America, Volume 28, Number 3, August 2001.

19. A Novel Human Cell Culture Model for the Study of Familial Prostate Cancer.
Yasunaga Y, Nakamura K, Ewing CM, Isaacs WB, Hukku B and Rhim JS:
Cancer Research, 61:5969-5973, August 2001.

20. Introduction to department of defense center for prostate disease research (CPDR) multicenter national prostate cancer database with 242,227 records on 11,637 men, and analysis of changes in the PSA-era.
Sun L, Gancarczyk K, McLeod DG, Kane C, Kusuda L, Lance R, Herring J, Foley J, Baldwin D, Bishoff JT, Soderdahl D, Wu H, Xu L, Moul JW.
Urol Oncol 2001.